2000年8月
Rebamipide, an antiulcer drug, prevents DSS-induced colitis formation in rats
DIGESTIVE DISEASES AND SCIENCES
- ,
- ,
- ,
- ,
- ,
- 巻
- 45
- 号
- 8
- 開始ページ
- 1608
- 終了ページ
- 1616
- 記述言語
- 英語
- 掲載種別
- DOI
- 10.1023/A:1005525313856
- 出版者・発行元
- KLUWER ACADEMIC/PLENUM PUBL
This study was conducted to investigate the efficacy of rebamipide against experimental colitis induced by dextran sulfate sodium (DSS) in a rat model of inflammatory bowel disease. Experimental colitis was induced in male Wistar rats by oral administration of 3% DSS solution for one week. The rats were provided with standard diet containing 0.105% rebamipide (160 mg/kg/day) for 1 week. In rats treated with rebamipide, clinical (body weight loss, bloody diarrhea, reduced physical activity, severe anemia, shortened colonic length, and perianal injury) and histopathological (pathological lesion score) findings of DSS colitis were significantly less than in rats with DSS colitis not treated with rebamipide. Rebamipide thus inhibited the induction of colitis. Rebamipide significantly reduced concentrations of both. interleukin-1 alpha and GRO/CINC-1 (IL-8-like substance) and cell infiltrates in colonic wall, in parallel with decreased activity of myeloperoxidase. It also reduced expression of IL-1 mRNA but did not influence expression of GRO/CINC-1 mRNA. The attenuation of colonic indices of colitis by rebamipide in this rat model suggests that this drug might have beneficial effects in the treatment of human ulcerative colitis. These effects of rebamipide are attributable to its inhibition of inflammatory cytokine-mediated granulocyte (neutrophil) infiltration into the colon.
- リンク情報
- ID情報
-
- DOI : 10.1023/A:1005525313856
- ISSN : 0163-2116
- Web of Science ID : WOS:000089429200018